Chengdu Enwei Pharmaceutical

Chengdu Enwei Pharmaceutical is a leading Chinese pharmaceutical enterprise primarily engaged in the research, development, and commercialization of Traditional Chinese Medicine (TCM) and chemical drugs. The company's core competency lies in gynecological health, where its flagship product, Jieeryin Lotion, has maintained a significant market share for decades. Enwei's product portfolio also extends into pediatrics, dermatology, and respiratory medicine, featuring both over-the-counter (OTC) and prescription treatments. Listed on the Shenzhen Stock Exchange since 2022, the company is focused on the modernization of TCM and expanding its chemical drug pipeline. Enwei operates integrated manufacturing facilities that adhere to national GMP standards to support its diverse product lines.